GIVAT SHMUEL, Israel--(BUSINESS WIRE)--Feb. 28, 2006--Gammacan International Inc.(OTC BB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that the Company filed two provisional applications for patents with the U.S. Patent and Trademark Office for a new and innovative treatment for malignant melanoma. The filings are detailed on a Form 8-K filed with the Securities and Exchange Commission on February 27th.
